Q/C Tech | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.19 22:16
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -2.5.

EBIT: As of FY2025 Q3, the actual value is USD -1.753 M.

Segment Revenue

  • No product revenue was reported for the three and nine months ended September 30, 2025 and 2024.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, the net loss was $2,811,388, compared to $1,929,391 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $5,732,326, compared to $21,295,080 for the same period in 2024.
  • General and Administrative Expenses: $967,833 for the three months ended September 30, 2025, compared to $1,104,130 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $2,703,815, compared to $3,149,041 for the same period in 2024.
  • Research and Development Expenses: $356,352 for the three months ended September 30, 2025, compared to $707,747 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $2,775,337, compared to $2,307,789 for the same period in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities was $5,865,877 for the nine months ended September 30, 2025, compared to $6,855,523 for the same period in 2024.
  • Investing Cash Flow: Net cash provided by investing activities was $3,245,029 for the nine months ended September 30, 2025, compared to net cash used of $7,202,955 for the same period in 2024.
  • Financing Cash Flow: Net cash provided by financing activities was $9,351,879 for the nine months ended September 30, 2025, compared to $13,926,528 for the same period in 2024.

Unique Metrics

  • Derivative Liabilities: The change in fair value of derivative liabilities resulted in a gain of $244,000 for the nine months ended September 30, 2025.

Future Outlook and Strategy

  • Core Business Focus: The company has shifted its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing. This includes leveraging an exclusive global licensing agreement with LightSolver Ltd. to deploy innovative laser processing units (LPUs).
  • Non-Core Business: The company is evaluating the potential divestiture of its Isomyosamine and Supera-CBD therapeutic platforms to fund its new strategic focus.
  • Priority: Over the next twelve months, the company anticipates finalizing qc-LPU100 prototypes, conducting internal performance benchmarking, securing patents, and initiating pilot testing with select AI and DePin Token users.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.